Every 8-K that Pediatrix Medical Group, Inc. (MD) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow MD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MD filings page.
Pediatrix Medical Group reported second-quarter 2026 net revenue of $487.8 million, up 4.0% from $468.8 million a year earlier. Net income was approximately $40 million, or diluted EPS of $0.49, while Adjusted EPS was $0.63 and Adjusted EBITDA was about $76 million.
Management attributed growth to 2.1% non-same-unit revenue expansion from recent acquisitions and 1.9% same-unit revenue growth. Same-unit revenue from reimbursement-related factors rose 4.0%, driven by improved cash collections, a more favorable payor mix and higher patient acuity, while same-unit patient volume declined 2.1% and commercial and other non-government payors increased by 135 basis points.
As of June 30, 2026, cash and cash equivalents were $288.9 million, total debt was $584.2 million and shareholders’ equity was $881.0 million. The company also outlined a forward-looking 2026 Adjusted EBITDA range between $280 million and $300 million.
Pediatrix Medical Group, Inc. reports that Mary Ann E. Moore, previously Executive Vice President, General Counsel, Chief Administrative Officer and Secretary, has entered into a Separation Agreement with subsidiary PMG Services, Inc. Under this agreement, she will serve in an advisory role until October 31, 2026, when her employment with the company will end.
The company states that Ms. Moore’s transition is treated as a termination without cause under her Second Amended and Restated Employment Agreement, and she will receive the benefits specified in that agreement. Pediatrix also reports the appointment of David Haddock as Executive Vice President, General Counsel and Secretary.
Pediatrix Medical Group, Inc. provided an update on second quarter 2026 business trends, noting that its payor mix remained stable and unchanged relative to recent historical trends and internal expectations, despite reports of adverse utilization and reimbursement shifts elsewhere in the healthcare sector.
The company stated it has not experienced unfavorable payor mix shifts or material changes in other net revenue-related trends. Pediatrix reaffirmed its full year 2026 outlook for Adjusted EBITDA in a range of $280 million to $300 million, supported by a reconciliation from net income. Pediatrix plans to discuss results for the quarter ended June 30, 2026 on an investor conference call and webcast on August 4, 2026 at 9:00 a.m. ET.
Pediatrix Medical Group, Inc. reported results from its 2026 Annual Shareholders’ Meeting. Shareholders approved the Second Amended and Restated 2008 Incentive Compensation Plan, increasing the number of common shares available for equity awards by 8,000,000 shares.
All director nominees were elected to serve until the 2027 Annual Shareholders’ Meeting, with each receiving over 69 million votes in favor, except one nominee who received lower support but was still elected. Shareholders also ratified PricewaterhouseCoopers LLP as independent auditor for the 2026 fiscal year and approved, on an advisory basis, executive compensation for 2025.
The meeting had strong participation, with 77,330,139 of 83,072,104 shares outstanding represented, constituting a quorum. The amended incentive plan and governance proposals are detailed further in the company’s previously filed proxy statement and attached exhibit.
Pediatrix Medical Group reported stronger first quarter 2026 results, with net revenue of $476.2 million for the three months ended March 31, 2026, up from $458.4 million a year earlier. Earnings were $0.36 per diluted share, and Adjusted EPS, which excludes items such as amortization, stock-based compensation and transformational and restructuring expenses, was $0.44.
Net income was $30 million and Adjusted EBITDA reached $58 million. Same-unit revenue grew 2.8 percent, driven mainly by a 4.4 percent increase in same-unit revenue from net reimbursement-related factors, reflecting better cash collections, higher hospital contract administrative fees, higher patient acuity and a slightly favorable payor mix. Same-unit patient volume declined by 1.6 percent.
As of March 31, 2026, Pediatrix reported cash and cash equivalents of $205.8 million, total debt of $590.8 million and total shareholders’ equity of $878.6 million.
Pediatrix Medical Group reported stronger profitability for the quarter and year ended December 31, 2025. For the fourth quarter, diluted EPS was $0.40, with Adjusted EPS of $0.50 on net revenue of $493.8 million, down slightly from $502.4 million a year earlier. Same-unit net revenue grew 4.0%, driven by a 6.7% increase from reimbursement-related factors, while same-unit patient service volumes declined 2.7%.
For full-year 2025, net income was $165.4 million versus a net loss of $99.1 million in 2024, translating to diluted EPS of $1.94 compared with a loss of $1.19. Adjusted EBITDA rose to $275.6 million from $224.0 million, and full-year Adjusted EPS increased to $2.04 from $1.51.
Liquidity and leverage also improved. Cash and cash equivalents increased to $375.2 million from $229.9 million, while total debt decreased to $597.3 million from $617.7 million. For 2026, the company projects Adjusted EBITDA between $280 million and $300 million.
Pediatrix Medical Group, Inc. filed an 8‑K announcing it furnished a press release with results for the three and nine months ended September 30, 2025. The information was provided under Item 2.02 and, along with Exhibit 99.1, is furnished and not deemed filed. The company’s common stock trades on the NYSE under the symbol MD.
Pediatrix Medical Group, Inc. disclosed that its Board of Directors has authorized a share repurchase program for up to $250 million of its outstanding common stock. The program gives the company flexibility to buy back shares over a three-year term, but it does not require Pediatrix to repurchase any specific dollar amount or number of shares.
Repurchases may occur through open market purchases, privately negotiated transactions, or trading plans established under Rule 10b5-1 and Rule 10b-18. The timing and actual level of repurchases will depend on factors such as the stock price, overall market and business conditions, legal requirements, and alternative uses of capital.